

10/538465
PATENT
JC17 Rec'd PCT/PTO 10 JUN 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Andrew Heath et al.

Application No.: To be assigned

Filed: To be assigned

Confirmation No.: To be assigned

For: VACCINE COMPRISING AN ANTIGEN
CONJUGATED TO LOW VALENCY
ANTI-CD40 OR ANTI-CD28
ANTIBODIES

Examiner: To be assigned

Art Unit: To be assigned

Attorney Reference No.: 5585-71231-01

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as Express Mail Label No. EV510808759US in an envelope addressed to: MAIL STOP PCT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent
for Applicant(s)

Date Mailed June 10, 2005

MAIL STOP PCT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(2)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this IDS is enclosed.


PATENT
10/538465
JC17 Rec'd PCT/PTO 10 JUN 2005

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By



Susan Alpert Siegel, B.D.
Registration No. 43,121

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

JC17 Rec'd PCT/PTO 10 JUN 2005

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	5585-71231-01
	Application Number	To be assigned
	Filing Date	To be assigned
	First Named Inventor	Andrew Heath
	Art Unit	To be assigned
	Examiner Name	To be assigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		US 2002/0086026 A1	04 July 2002	Heath
		US 2002/0098184 A1	25 July 2002	Heath

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO/PCT	WO 01/26608 A2	19 April 2001	Ledbetter et al.

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
		Barr et al., <i>Immunology</i> 109:87-92, 2003
		Carlring et al., <i>Eur. J. Immunol.</i> 33:135-142, 2003
		Fanslow et al., <i>Seminars in Immunology</i> 6:267-278, 1994
		Xiang et al., <i>Journal of Immunology</i> 167:4560-4565, 2001

EXAMINER SIGNATURE: /Phillip Gambel/	DATE CONSIDERED: 07/07/2008
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	